Stephane Peluso - 02 Aug 2022 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC.

Role: Chief Scientific Officer
Signature: /s/ Stephane Peluso
Issuer symbol: N/A
Transactions as of: 02 Aug 2022
Net transactions value: +$9,932
Form type: 4
Filing time: 04 Aug 2022, 18:26:16 UTC
Previous filing: 12 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INFI	Common Stock	Options Exercise		+50,000	+2444%		52,046	02 Aug 2022	Direct	F1
transaction	INFI	Common Stock	Sale	$9,932	+14,994	+68%	$0.6624^*	37,052	02 Aug 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INFI	Restricted Stock Unit	Options Exercise	$0	-50,000	-100%	$0.000000^*	0	02 Aug 2022	Common Stock	50,000		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date.
F2	Represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3	On August 2, 2021, the reporting person was granted RSUs, of which all 50,000 vested as of August 2, 2022.